



LONDON IEI:

A CONTINUUM FROM MECHANISM TO MANAGEMENT

Thursday 21 January 2027, 9:00-18:00 GMT

08:30-09:00	Registration for those attending in person. Those joining online to log in at 08:58	
09:00-13:30	Session 1: WAS and beyond	
09:00-9:30	X-Linked thrombocytopenia: is it a mislabel?	Bénédicte Neven , Professor of Pediatrics, Hôpital Necker-Enfants Malades, Paris, France
9:30-10:00	Immunometabolism in Wiskott Aldrich Syndrome with reflection from clinic	Elizabeth Rivers , Consultant in Paediatric Immunology, GOSH, UK
10:00-10:30	Actinopathies beyond WAS: Linking autoimmunity, autoinflammation and immunodeficiency	Kaan Boztug , Director, Clinic for Pediatric Immunology and Rheumatology, University Hospital Bonn, Germany; Professor of Pediatrics, Medical University and St. Anna Children's Cancer Research Institute, Vienna, Austria
10:30-11:00	Discussion on management approach	
11:00-11:30	Break	
11:30-12:00	CARD11: disease spectrum and management approach	Fabian Hauck , Director University Children's Hospital Mannheim, University Children's Hospital Heidelberg – Mannheim Ltd. Pediatrics / Pediatric Hematology and Oncology / Cellular Therapy / Immunology
12:00-12:30	Managing IKAROS- associated IEI: How LOF and GOF mutations dictate therapy	Sergio Rosenzweig , Chief of the Immunology Service, NIH Clinical Center, National Institutes of Health, USA
12:30-13:00	New frontiers in familial HLH: RhoG and other genetic etiologies	Kaan Boztug , Director, Clinic for Pediatric Immunology and Rheumatology, University Hospital Bonn, Germany; Professor of Pediatrics, Medical University and St. Anna Children's Cancer Research Institute, Vienna, Austria
13:00-13:30	Discussion	
13:30-14:30	Lunch Break	
14:30-16:00	Session 2: Genetic Jeopardy - Stop guessing - start acting	
14:30-15:00	Interpreting panel: Red flags /false reassurances	Kimberly Gilmour , Clinical Lead of Immunology Laboratory, GOSH, UK and Anthony Gait , Clinical Scientist, GOSH
15:00-15:30	When carrier status is no longer benign: lessons from AIRE, DADA2 and beyond?	Isabelle Meyts , Consultant in Paediatric Haemato-oncology, University Ziekenhuis Leuven, Belgium
15:30-16:00	Discussion	
16:00-16:30	Break	



LONDON IEI:

A CONTINUUM FROM MECHANISM TO MANAGEMENT

16:30-18:00	Session 3: The hidden manifestations of IEI	
16:30-16:50	Malignancy in IEI: Who presents first and How do we treat? Answers from the ESID registry	Nizar Mahlouli , Pediatrician and Head of the Reference Center for Hereditary Immune Deficiencies in Children and Adults (CEREDIH), Hôpital Necker-Enfants Malades, Paris, France
16:50-17:10	Gastrointestinal manifestations in IEI: does it matter which disease?	Kelsey Jones , Consultant in Paediatric Gastroenterology, GOSH, UK
17:10-17:30	Pattern recognition of syndromic immunodeficiency	Maaïke Kusters , Consultant in Paediatric Immunology, GOSH, UK
17:30-18:00	Discussion	
18:00	End of day 1	

Friday 22 January 2027, 9:00-17:30 GMT

08:45-9:00	Arrival for those attending in person. Those joining online to log in at 08:58	
09:00-11:30	Session 4: Visiting an old IEI	
09:00-9:30	CGD- Infection- inflammation a balancing act for effective therapy	Christa Zerbe , Medical Director of Clinical Services, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, USA
9:30-10:00	Cellular therapy in CGD: what did we learn across the years and what we do?	Tayfun Güngör , Professor of Paediatrics and Stem Cell Transplantation, Consultant Paediatric Haematologist and Immunologist, University Children's Hospital Zurich, Switzerland
10:00-10:30	Carriers of XL-CGD from clinic to management approach	Susan Tadros , Consultant in Adult Immunology, Royal Free London, UK
10:30-11:00	Running a CGD service: nursing perspective and patient perspective	Helen Braggins , Clinical Nurse Specialist (SCIDS), GOSH, UK
11:00-11:30	Discussion	
11:30-12:00	Break	
12:00-13:30	Session 5: Gene therapy in IEI	
12:00-12:30	Viral vector gene therapy in IEI: what can we offer patients today and what is next?	Alessandro Aiuti , Head of the Pediatric Immunohematology Unit, IRCCS San Raffaele Hospital, Milan; Full Professor of Pediatrics, Vita-Salute San Raffaele University, Italy
12:30-13:00	Gene editing in IEI: the first patient cases and what we have learned	Suk See De Ravin , Senior Research Physician & Chief, Gene Therapy Development Unit, Laboratory of Clinical Immunology &



LONDON IEI:

A CONTINUUM FROM MECHANISM TO MANAGEMENT

		Microbiology, National Institute of Allergy and Infectious Diseases, NIH, USA
13:00-13:30	Discussion	
13:30-14:30	Lunch Break	
14:30-16:00	Session 6: Is it ever truly over - Before and After approach	
14:30-14:50	Autoimmunity: When do you stop treating and start transplanting?	Juliana Silva , Consultant in Bone Marrow Transplant and CAR-T Cell Therapy, GOSH, UK
14:50-15:10	Long-term outcome post-HSCT for IEI - what did we observe?	Reem Elfeky , Consultant in Paediatric Immunology, GOSH, UK
15:10-15:30	Long-term outcome post- GT for ADA SCID	Maria Pia Cicalese , Consultant Pediatrician, San Raffaele Scientific Institute, Milan, Italy; Assistant Professor of Pediatrics, University Vita-Salute San Raffaele of Milan, Italy
15:30-16:00	Discussion	
16:00-16:30	Break	
16:30-17:30	Session 7: Lab session and case presentation	
17:30	End	